Tacoma, WA (PRWEB) November 06, 2012
Revalesio’s novel therapeutic RNS60 prevented memory loss and improved learning in a mouse model of Alzheimer’s disease. Researchers from Rush University and Revalesio Corporation presented the research at the Society for Neuroscience (SFN) annual meeting (October 13-17) in New Orleans. In addition to improved memory and learning, the animals treated with RNS60 had significantly reduced levels of cellular markers associated with Alzheimer’s disease compared to untreated mice.
Alzheimer’s disease (AD) is the most common cause of senile dementia in the US and Europe. AD is characterized by progressive cognitive impairment, beginning as memory loss but eventually involving multiple cognitive and behavioral domains.
Earlier research demonstrated that RNS60, a novel anti-inflammatory therapeutic containing charge-stabilized oxygen nanobubble-based structures, inhibits the expression of proinflammatory molecules and glial activation markers in cultured glial (brain) cells. The research presented at SFN demonstrated that injection of RNS60 reduced the activation of glial cells in the brains of mice and protected the memory and learning in mice that were genetically modified to develop Alzheimer’s disease (FAD 5X transgenic mice).
In addition to protecting the memory and learning functions, levels of inflammatory markers in the brain were significantly lower in RNS60-treated mice compared to the control groups (untreated transgenic mice or normal saline treated transgenic mice). RNS60 significantly reduced memory impairment in FAD 5X transgenic mice compared to untreated animals. Learning and memory functions in RNS60-treated animals were indistinguishable from those of non-transgenic, normal mice. These results demonstrate the promise of RNS60 as a new therapy for AD by modulating glial activation and neuroinflammation.
Revalesio is pursuing additional research into AD in conjunction with Dr. Kalipada Pahan at Rush University Medical Center and with Dr. Rodolfo Llinas at New York University’s Langone Medical Center. Researchers from Rush University and Revalesio are preparing a manuscript for publication in a scientific journal. Revalesio is preparing to study RNS60 in Multiple Sclerosis with a Phase II clinical trial at Mt. Sinai Hospital in New York.
Revalesio has pioneered the use of RNS60 as a therapeutic that alters whole cell conductance through effects on voltage-gated ion channels and other voltage-sensing proteins, thereby modulating the activity of G protein-coupled receptors and the secretion of cytokines, chemokines resulting in decreased inflammation and cell death. RNS60 contains charge-stabilized nanostructures (CSN) that are created by subjecting normal saline to Taylor-Couette-Poiseuille (TCP) flow. RNS60 has demonstrated a reduction in inflammatory responses that are linked to numerous diseases, including neurodegenerative, respiratory and cardiovascular diseases.
About Revalesio Corporation
Revalesio is a pioneering clinical stage biomedical company dedicated to restoring hope and transforming lives. Founded in 2000 and based in Tacoma, Washington, Revalesio has partnered with leaders in biomedical research around the world to develop RNS60. Revalesio has an extensive patent portfolio on a novel class of anti-inflammatory products and is advancing the use of CSN in neuro-inflammatory, respiratory, cardiovascular and other inflammatory diseases. For more information about Revalesio, visit revalesio.com.